Clinical translation of targeted α-therapy: an evolution or a revolution?
The field of radioligand therapy has advanced greatly in recent years, driven largely by β-emitting therapies targeting somatostatin receptor-expressing tumors and the prostate-specific membrane antigen. Now, more clinical trials are under way to evaluate α-emitting targeted therapies as potential n...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May 2023
|
| In: |
Journal of nuclear medicine
Year: 2023, Jahrgang: 64, Heft: 5, Pages: 685-692 |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.122.265353 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2967/jnumed.122.265353 Verlag, lizenzpflichtig, Volltext: https://jnm.snmjournals.org/content/64/5/685 
|
| Verfasserangaben: | Benedikt Feuerecker, Clemens Kratochwil, Hojjat Ahmadzadehfar, Alfred Morgenstern, Matthias Eiber, Ken Herrmann, and Kelsey L. Pomykala |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1854277065 | ||
| 003 | DE-627 | ||
| 005 | 20240307063540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230803s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2967/jnumed.122.265353 |2 doi | |
| 035 | |a (DE-627)1854277065 | ||
| 035 | |a (DE-599)KXP1854277065 | ||
| 035 | |a (OCoLC)1425213560 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Feuerecker, Benedikt |e VerfasserIn |0 (DE-588)1062977068 |0 (DE-627)807088455 |0 (DE-576)420314628 |4 aut | |
| 245 | 1 | 0 | |a Clinical translation of targeted α-therapy |b an evolution or a revolution? |c Benedikt Feuerecker, Clemens Kratochwil, Hojjat Ahmadzadehfar, Alfred Morgenstern, Matthias Eiber, Ken Herrmann, and Kelsey L. Pomykala |
| 246 | 3 | 3 | |a Clinical translation of targeted alpha-therapy |
| 264 | 1 | |c May 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 28. April 2023 | ||
| 500 | |a Gesehen am 03.08.2023 | ||
| 520 | |a The field of radioligand therapy has advanced greatly in recent years, driven largely by β-emitting therapies targeting somatostatin receptor-expressing tumors and the prostate-specific membrane antigen. Now, more clinical trials are under way to evaluate α-emitting targeted therapies as potential next-generation theranostics with even higher efficacy due to their high linear energy and short range in human tissues. In this review, we summarize the important studies ranging from the first Food and Drug Administration-approved α-therapy, 223Ra-dichloride, for treatment of bone metastases in castration-resistant prostate cancer, including concepts in clinical translation such as targeted α-peptide receptor radiotherapy and 225Ac-PSMA-617 for treatment of prostate cancer, innovative therapeutic models evaluating new targets, and combination therapies. Targeted α-therapy is one of the most promising fields in novel targeted cancer therapy, with several early- and late-stage clinical trials for neuroendocrine tumors and metastatic prostate cancer already in progress, along with significant interest and investment in additional early-phase studies. Together, these studies will help us understand the short- and long-term toxicity of targeted α-therapy and potentially identify suitable therapeutic combination partners. | ||
| 650 | 4 | |a 225Ac | |
| 650 | 4 | |a PSMA-617 | |
| 650 | 4 | |a targeted α-therapy | |
| 650 | 4 | |a α-emitter | |
| 700 | 1 | |a Kratochwil, Clemens |d 1978- |e VerfasserIn |0 (DE-588)134026276 |0 (DE-627)559871686 |0 (DE-576)300262787 |4 aut | |
| 700 | 1 | |a Ahmadzadehfar, Hojjat |e VerfasserIn |4 aut | |
| 700 | 1 | |a Morgenstern, Alfred |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eiber, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herrmann, Ken |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pomykala, Kelsey L. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear medicine |d New York, NY : Soc., 1964 |g 64(2023), 5 vom: Mai, Seite 685-692 |h Online-Ressource |w (DE-627)325793603 |w (DE-600)2040222-3 |w (DE-576)09475277X |x 2159-662X |7 nnas |a Clinical translation of targeted α-therapy an evolution or a revolution? |
| 773 | 1 | 8 | |g volume:64 |g year:2023 |g number:5 |g month:05 |g pages:685-692 |g extent:8 |a Clinical translation of targeted α-therapy an evolution or a revolution? |
| 856 | 4 | 0 | |u https://doi.org/10.2967/jnumed.122.265353 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://jnm.snmjournals.org/content/64/5/685 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230803 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 134026276 |a Kratochwil, Clemens |m 134026276:Kratochwil, Clemens |d 910000 |d 911400 |e 910000PK134026276 |e 911400PK134026276 |k 0/910000/ |k 1/910000/911400/ |p 2 | ||
| 999 | |a KXP-PPN1854277065 |e 4362740171 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"physDesc":[{"noteIll":"Illustrationen","extent":"8 S."}],"title":[{"title_sort":"Clinical translation of targeted α-therapy","subtitle":"an evolution or a revolution?","title":"Clinical translation of targeted α-therapy"}],"person":[{"family":"Feuerecker","role":"aut","given":"Benedikt","display":"Feuerecker, Benedikt"},{"display":"Kratochwil, Clemens","given":"Clemens","role":"aut","family":"Kratochwil"},{"display":"Ahmadzadehfar, Hojjat","family":"Ahmadzadehfar","given":"Hojjat","role":"aut"},{"family":"Morgenstern","role":"aut","given":"Alfred","display":"Morgenstern, Alfred"},{"display":"Eiber, Matthias","family":"Eiber","given":"Matthias","role":"aut"},{"display":"Herrmann, Ken","given":"Ken","role":"aut","family":"Herrmann"},{"given":"Kelsey L.","role":"aut","family":"Pomykala","display":"Pomykala, Kelsey L."}],"recId":"1854277065","name":{"displayForm":["Benedikt Feuerecker, Clemens Kratochwil, Hojjat Ahmadzadehfar, Alfred Morgenstern, Matthias Eiber, Ken Herrmann, and Kelsey L. Pomykala"]},"origin":[{"dateIssuedDisp":"May 2023","dateIssuedKey":"2023"}],"id":{"eki":["1854277065"],"doi":["10.2967/jnumed.122.265353"]},"titleAlt":[{"title":"Clinical translation of targeted alpha-therapy"}],"note":["Online veröffentlicht: 28. April 2023","Gesehen am 03.08.2023"],"relHost":[{"part":{"pages":"685-692","volume":"64","text":"64(2023), 5 vom: Mai, Seite 685-692","extent":"8","issue":"5","year":"2023"},"note":["Gesehen am 13.12.2021"],"titleAlt":[{"title":"JNM"}],"pubHistory":["Nachgewiesen 5.1964 -"],"name":{"displayForm":["Society of Nuclear Medicine"]},"recId":"325793603","disp":"Clinical translation of targeted α-therapy an evolution or a revolution?Journal of nuclear medicine","id":{"eki":["325793603"],"issn":["2159-662X","1535-5667"],"zdb":["2040222-3"]},"origin":[{"publisherPlace":"New York, NY","publisher":"Soc.","dateIssuedKey":"1964","dateIssuedDisp":"1964-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"role":"isb","display":"Society of Nuclear Medicine"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Journal of nuclear medicine","subtitle":"JNM","title_sort":"Journal of nuclear medicine"}]}]} | ||
| SRT | |a FEUERECKERCLINICALTR2023 | ||